Desonide Generic Name & Formulations
Desonide 0.05%; gel; alcohol-, fragrance-, surfactant-free.
Mild to moderate atopic dermatitis.
Desonide Dosage and Administration
Adults and Children
<3mos: not recommended. ≥3mos: apply thin layer to affected area(s) twice daily; max 4 weeks of therapy. Do not occlude.
Do not use superpotent forms on face, groin, or axillae. Exclude viral disease (eg, chickenpox, measles).
Desonide Boxed Warnings
Treat infection if present; discontinue if infection persists or worsens. Do not use near eyes, or on diaper dermatitis or pre-existing skin atrophy. Do not use fluorinated steroids longer than 1 week on the face. Avoid abrupt cessation in chronic use. Systemic absorption increased by broken or inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Occlude only if necessary; do not occlude higher potency products. Monitor adrenal function in children if a high potency product or occlusion is used, and in adults if more than 50g weekly of a high potency product is used. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Use lowest effective dose and potency (esp. in children). Use caution if applying to face or body folds. Do not use continuously or for prophylaxis. Foams are flammable. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Desonide Adverse Reactions
Burning, stinging, pruritus, erythema, skin atrophy, striae, miliaria, secondary infections, hypopigmentation, folliculitis, hypertrichosis, acneiform eruptions, dermal cracking and fissuring, telangiectasia, contact dermatitis, other local effects, immunosuppression, masks infections, HPA axis suppression (esp. in children).
Desonide Clinical Trials
Formerly known under the brand name Desonate.
Desonide Patient Counseling